Merus (MRUS) Competitors $67.49 +0.84 (+1.26%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$67.48 0.00 (-0.01%) As of 08/22/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. SMMT, GMAB, VTRS, RDY, ASND, MRNA, QGEN, BBIO, VRNA, and ELANShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Qiagen (QGEN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Merus vs. Its Competitors Summit Therapeutics Genmab A/S Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Qiagen BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Summit Therapeutics (NASDAQ:SMMT) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk. Do analysts prefer SMMT or MRUS? Summit Therapeutics currently has a consensus price target of $32.85, suggesting a potential upside of 25.37%. Merus has a consensus price target of $88.50, suggesting a potential upside of 31.13%. Given Merus' stronger consensus rating and higher probable upside, analysts clearly believe Merus is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 3 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.63Merus 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Which has more risk & volatility, SMMT or MRUS? Summit Therapeutics has a beta of -1.06, indicating that its stock price is 206% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Which has stronger earnings and valuation, SMMT or MRUS? Merus has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit TherapeuticsN/AN/A-$221.32M-$1.01-25.94Merus$36.13M141.28-$215.33M-$5.50-12.27 Is SMMT or MRUS more profitable? Summit Therapeutics has a net margin of 0.00% compared to Merus' net margin of -685.64%. Merus' return on equity of -50.28% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -208.64% -181.28% Merus -685.64%-50.28%-42.00% Do insiders & institutionals have more ownership in SMMT or MRUS? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Merus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer SMMT or MRUS? In the previous week, Summit Therapeutics had 7 more articles in the media than Merus. MarketBeat recorded 12 mentions for Summit Therapeutics and 5 mentions for Merus. Merus' average media sentiment score of 1.71 beat Summit Therapeutics' score of 0.51 indicating that Merus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Merus 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryMerus beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.10B$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E Ratio-12.2721.0031.3626.05Price / Sales141.28209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book6.068.129.536.60Net Income-$215.33M-$54.72M$3.26B$265.65M7 Day Performance0.36%2.62%2.14%2.00%1 Month Performance2.74%3.25%3.22%0.46%1 Year Performance25.94%10.82%30.19%18.88% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus2.303 of 5 stars$67.49+1.3%$88.50+31.1%+25.9%$5.10B$36.13M-12.2737News CoveragePositive NewsSMMTSummit Therapeutics2.3802 of 5 stars$26.29-1.5%$35.00+33.1%+100.3%$19.53BN/A-26.03110Analyst ForecastGMABGenmab A/S3.8468 of 5 stars$23.42+0.5%$37.60+60.5%-9.8%$15.02B$3.12B11.772,682Positive NewsAnalyst DowngradeVTRSViatris1.6099 of 5 stars$10.63+0.2%$10.40-2.2%-9.4%$12.39B$14.74B-3.6732,000Analyst UpgradeRDYDr. Reddy's Laboratories3.134 of 5 stars$14.26+0.2%$16.95+18.9%-11.7%$11.90B$3.81B21.6027,811News CoveragePositive NewsASNDAscendis Pharma A/S3.4351 of 5 stars$194.08-2.1%$242.93+25.2%+39.1%$11.88B$393.54M-37.611,017News CoverageAnalyst ForecastMRNAModerna4.5059 of 5 stars$28.09+0.2%$43.59+55.2%-67.1%$10.93B$3.24B-3.735,800News CoverageAnalyst ForecastQGENQiagen3.8252 of 5 stars$48.66-1.4%$49.69+2.1%+10.5%$10.82B$1.98B28.755,765News CoveragePositive NewsBBIOBridgeBio Pharma4.6761 of 5 stars$49.02-4.5%$61.35+25.2%+93.9%$9.37B$221.90M-11.99400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.3884 of 5 stars$105.79+0.5%$109.00+3.0%+292.7%$9.01B$42.28M-106.8630News CoveragePositive NewsShort Interest ↓ELANElanco Animal Health3.0855 of 5 stars$17.72-1.4%$17.33-2.2%+22.9%$8.80B$4.44B20.609,000Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies Summit Therapeutics Competitors Genmab A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Moderna Competitors Qiagen Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 8/24/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access